Published in:
01-09-2019 | Diabetes Therapy | Letter
CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]
Authors:
Gisela M. Vaitaitis, Michael H. Olmstead, Dan M. Waid, Jessica R. Carter, David H. Wagner Jr.
Published in:
Diabetologia
|
Issue 9/2019
Login to get access
Excerpt
To the Editor: We appreciate the letter by Pagni et al [
1] that comments on our previous publication [
2]. However, rather than definitively demonstrating that the KGYY
15 peptide does not work in pre-clinical studies, their report highlights the complexities of CD40 as a molecule and strengthens the need for a better understanding of CD40. It is easy to think that a molecule that has been studied for so long is fully understood when in reality the opposite is true. …